718 
Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, and Cerner, a global supplier of healthcare solutions and electronic health record (EHR) technology, have announced an agreement that will provide biopharma sponsors in the UK and abroad with research and technology services to help them quickly evaluate the benefits and side effects of therapeutic treatments currently on the market.
Regulators and payers are increasingly calling for more post-marketing research, specifically observational studies and registries. These late phase research studies offer opportunities to establish long-term product safety, pursue expanded indications for use, and strengthen the understanding of a product’s short-term and long-term value.
“Through Quintiles’ collaboration with Cerner, we now can offer biopharmaceutical organisations globally including those in England and Ireland an integrated solution for conducting patient registries, post-approval and late phase studies, observational studies, and studies to support Risk Evaluation and Mitigation Strategies (REMS),” said Dr Dipti Amin, Quintiles Senior Vice President of Drug Safety and Medical Affairs.
“This then marries our clinical study design and operations expertise with their technical depth and understanding of clinical workflows.”
